biophytis®

NEW THERAPEUTICS FOR DISEASES OF AGING

THE BIOTECH SPECIALISED IN DISEASES OF AGING

DISCLAIMER

Important Information and Forward Looking Statements

- BIOPHYTIS IS A PUBLIC COMPANY LISTED ON THE ALTERNEXT MARKET OF EURONEXT PARIS STOCK EXCHANGE SINCE JULY 13, 2015.
- THIS DOCUMENT DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER FOR SALE OR SUBSCRIPTION OF OR SOLICITATION OF ANY OFFER TO BUY OR SUBSCRIBE FOR ANY SECURITIES.
- THE SHARES OF BIOPHYTIS HAVE NOT BEEN AND ARE NOT BEING REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT") AND NEITHER BIOPHYTIS, ITS SHAREHOLDERS OR THEIR AFFILIATES INTEND TO REGISTER ITS SHARES IN THE UNITED STATES OR TO CONDUCT A PUBLIC OFFERING OF SECURITIES IN THE UNITED STATES. SECURITIES MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES UNLESS THEY ARE REGISTERED UNDER THE SECURITIES ACT, OR EXEMPT FROM REGISTRATION.
- BASED ON ITS HISTORIC AND EXPECTED OPERATIONS, COMPOSITION OF ASSETS AND MARKET CAPITALIZATION (WHICHWILL FLUCTUATE FROM TIME TO TIME), BIOPHYTIS DOES NOT EXPECT THAT IT WILL BE A "PASSIVE FOREIGN INVESTMENT COMPANY" WITHIN THE MEANING OF SECTION 1297 OF THE U.S. INTERNAL REVENUE CODE OF 1986, AS AMENDED, (A "PFIC") FOR THE CURRENT TAXABLE YEAR. HOWEVER, THE DETERMINATION OF WHETHER BIOPHYTIS IS A PFIC IS MADE ANNUALLY, AFTER THE CLOSE OF THE RELEVANT TAXABLE YEAR, AND, THEREFORE, IT IS POSSIBLE THAT BIOPHYTIS COULD BE CLASSIFIED AS A PFIC FOR THE CURRENT TAXABLE YEAR OR ANY FUTURE TAXABLE YEAR DUE TO CHANGES IN THE COMPOSITION OF ITS ASSETS OR INCOME, AS WELL AS CHANGES IN ITS MARKET CAPITALIZATION.
- THIS DOCUMENT INCLUDES CERTAIN STATEMENTS OF THE COMPANY WITH RESPECT TO THE COMPANY'S HISTORICAL AND ANTICIPATED FUTURE PERFORMANCE. SUCH STATEMENTS REFLECT VARIOUS ASSUMPTIONS OF MANAGEMENT THAT MAY OR MAY NOT PROVE TO BE CORRECT AND INVOLVE VARIOUS RISKS AND UNCERTAINTIES. NO REPRESENTATIONS OR WARRANTIES ARE MADE AS TO THE ACCURACY OF SUCH STATEMENTS OF ANTICIPATED PERFORMANCE.
- CERTAIN OF THE INFORMATION CONTAINED HEREIN CONCERNING ECONOMIC TRENDS AND PERFORMANCE IS BASED UPON OR DERIVED FROM INFORMATION PROVIDED BY THIRD-PARTY CONSULTANTS AND OTHER INDUSTRY SOURCES. THE COMPANY BELIEVES THAT SUCH INFORMATION IS ACCURATE AND THAT THE SOURCES FROM WHICH IT HAS BEEN OBTAINED ARE RELIABLE. THE COMPANY CAN'T GUARANTEE THE ACCURACY AND COMPLETENESS OF SUCH INFORMATION, HOWEVER, AND THE COMPANY HAS NOT INDEPENDENTLY VERIFIED THE ASSUMPTIONS ON WHICH PROJECTIONS OF FUTURE TRENDS AND PERFORMANCE ARE BASED.
- EXCEPT AS OTHERWISE INDICATED, THIS DOCUMENT SPEAKS AS OF THE DATE HEREOF. THE DELIVERY OF THIS DOCUMENT SHALL NOT, UNDER ANY CIRCUMSTANCES, CREATE ANY IMPLICATION THAT THERE HAS BEEN NO CHANGE IN THE AFFAIRS OF THE COMPANY AFTER THE DATE HEREOF.

CORPORATE OVERVIEW

BIOPHYTIS is a public company listed on Euronext Growth (Paris, France)

- Share price (August 30th 2018): €2.61
- Shares outstanding: 13,463,413
- Market capitalization: €35M
- €16M raised in 2015; €28M raised in 2017

BIOPHYTIS is advancing two drug candidates into Phase II

SARCONEOS	MACUNEOS
MAS activator	PPAR activator
Sarcopenia Phase 2b start H1 2018	Dry AMD Phase 1/2a start H2 2018
DMD Phase 2/3 planned for 2019	Stargardt Phase 2/3 planned for 2020

BIOPHYTIS spun-out of Sorbonne Université in 2006

- Aging science platform made of long-term collaboration with Sorbonne University (Institut de Biologie Paris-Seine, Institut de Myologie, Institut de la Vision)
- Development of small molecules blocking degenerative processes of aging selected through reverse pharmacology from a collection of plant secondary metabolites

THE TEAM

Stanislas VEILLET
Founder & CEO
- PhD in genetics, AgroParisTech alumnus
- 15+ years in R&D management (Monsanto, Pharmacia, Danone)
- Created Biophytis in 2006

René LAFONT
Co-founder & CSO
- Professor emeritus at Sorbonne Université
- Former Dean of the life sciences department
- 170+ peer-reviewed publications

A SEASONED MANAGEMENT TEAM

Jean-Christophe MONTIGNY
Chief Financial Officer
- AgroParisTech engineer, BA from IEP Paris
- 20+ years management experience in fast growing businesses
- Joined Biophytis in 2009

Samuel AGUS
Chief Medical Officer
- MD, PhD
- Board-certified Neurologist
- 15+ years pharma/biotech experience
- Joined Biophytis in 2018

Manfred HORST
Business Development Officer
- MD, PhD, MBA
- 30+ years pharma industry experience
- 12 years Business Development for MSD

DRUG DISCOVERY & DEVELOPMENT STRATEGY

First generation

- Active principles derived from plant substances
- Preclinical proof of concept
- Well tolerated in humans
- IP on use and process

Second generation

- New chemical entities
- Optimized pharmacology
- IP on composition of matter



Biophytis has identified small molecules derived from plants which counteract the effects of stress on cellular function and slow down degenerative processes associated with aging

PIPELINE


CANDIDATES
INDICATION
PRECLINICAL
PHASE I
PHASE II
PHASE III
SARCONEOS
SARCOPENIA
DMD
BIO 103
OTHER MUSCLES DYSTROPHIES
MAS ACTIVATORS
MACUNEOS
DRY AMD
STARGARDT
BIO 203
OTHER RETINAL DISORDERS
PPAR ACTIVATORS

SCIENTIFIC BOARD

Pr. Jean MARIANI
Director of Institut de la longévité Charles Foix



Pr. René LAFONT
Professor emeritus
Former Dean of the life sciences department

Pr. José SAHEL
Director of Institut de la Vision

WORLD CLASS SCIENTIFIC LEADERS CONTRIBUTE TO THE DEVELOPMENT OF OUR DRUG CANDIDATES

Dr. Roger FIELDING
Professor Nutrition Science, Harvard Medical School
Director Clinical Nutrition Unit

Dr. Thomas VOIT
Professor, University College London,
Director of the Research Centre of the GOSH for Children

Dr. Ivana KIM
Professor Harvard Medical School,
Director Retina Research, MEEI

MAS ACTIVATORS AND MUSCULAR DISEASES

GERIATRIC CHRONIC DISEASE:
SARCOPENIA

PAEDIATRIC ORPHAN DISEASE
DUCHENNE'S MUSCULAR DYSTROPHY (DMD)

RENIN ANGIOTENSIN SYSTEM (RAS) AND MUSCLE ANABOLISM



Targeting RAS stimulates anabolism in muscle and has potential for the treatment of chronic or genetic muscle disorders

MAS ACTIVATION



SARCONEOS is a potent MAS activator that stimulates protein synthesis, energy production and regeneration in muscle

SARCOPENIA



- Definition: Low muscle strength and low muscle mass (FNIH criteria)
  ICD-10 Code: M62.84
- Prevalence: 50M patients
  Estimated at 5 – 10% in >65 years old
- Standard of Care: 30 minutes physical exercise / day
  No currently approved medication

Drug candidates in development	Examples
Myostatin Inhibitors	Antibodies (e.g. Bimagrumab / Novartis) Increase muscle mass and strength, but do not improve mobility
Selective Androgen Receptor Modulators (SARMs)	Enobosarm (GTx / Merck), no longer developed for sarcopenia
Troponin Complex Inhibitor	CK-107 (Cytokinetics / Astellas), developed for COPD and SMA
MAS Activators	SARCONEOS (Biophytis)

SARCONEOS: PROOF OF CONCEPT IN ANIMALS

SARCONEOS compensates the effect of ageing on muscle functionality and mobility



Increase in running speed in old mice

SARCONEOS stimulates anabolism in muscle



Increase in protein quantity in muscle



Inhibition of myostatin expression in muscle

SARCONEOS stimulates anabolism and compensates the effect of ageing on muscle functionality and mobility in mice and rat models of sarcopenia

SARCONEOS: PROOF OF ACTIVITY IN NUTRITIONAL TRIAL

QUINOLIA – Safety, PK and pharmacodynamic parameters in obese healthy volunteers

- 58 subjects, double-blind, placebo-controlled, nutrition study (dieting)
- Oral administration (40 mg/day) for 12 weeks (6 weeks hypocaloric dieting)
- No serious adverse event and good safety profile in young obese subjects

Treatment compensates the diet's effect on muscular strength



Lesser muscle strength loss (grip test, p=0.09)

Treatment accentuates diet's effect both on androïd fat mass and resistance to insulin



Stimulation of androïd fat mass loss (%, p=0.04)



Reduction of insulin resistance (Homa-IR index, p=0,06)

SARCONEOS active molecule increases the muscle strength, significantly reduces both the androïd fat mass and the resistance to insulin in obese healthy volunteers

SARCONEOS: PROOF OF SAFETY IN PHASE I STUDY

SARA-PK – Phase 1 – Safety, PK and PD in elderly healthy volunteers

- 54 elderly subjects (>65 years), combined SAD (24 elderly and young subjects) + MAD step (30 elderly subjects)
- MAD after oral administration of 350 mg/day, 700 mg/day or 900 mg/day for 14 days
- No serious adverse event and good safety profile in elderly subjects
- Good pharmacokinetics profile, not influenced by age or meal
- The analysis of pharmacodynamics biomarkers confirms the stimulation of muscular anabolism and the activation of the RAS system in strong doses

SARCONEOS stimulates muscular anabolism and reduces catabolism (biomarkers)



Plasmatic level of type III Procollagen Propeptide (PIIINP, R^2= 0,88) and Myoglobin (R^2=0,65) according to SARCONEOS' doses

SARCONEOS has a good safety and PK profile in young and elder subjects, with *indication* of activity on various biomarkers

SARA: PHASE 2b INTERNATIONAL CLINICAL PROGRAM

SARA-OBS - Observational study

- Multicentric observational study: eight clinical centers in Europe and the US
- Recruitment of sarcopenic patients in Europe and US on going
- 300 sarcopenic patients: Foundation of NIH inclusion criteria for sarcopenia
- Duration: Six months
- Endpoints: 6mn walk test, 400 meters gait speed test, electronically recorded patient-reported outcomes (ePROs): SF-36 QOL questionnaire, measures of muscle strength and muscle mass, plasmatic biomarkers

SARA–INT – Interventional study

- Multicentric, double-blind, randomized and placebo-controlled
- 334 sarcopenic patients from SARA-OBS and new clinical centers
- Sarconeos 175 mg BID vs 350 mg BID vs Placebo
- Duration: 26 weeks
- Endpoints (EMEA Scientific Advice):
  - Primary: **400 meters gait speed test**
  - Secondary: **ePROs (PF-10 subscore of SF-36), Raising from a chair**; 6mn walk test, stair climbing power test, muscle strength & muscle mass



DUCHENNE'S MUSCULAR DYSTROPHY (DMD)

- Definition: Genetic disease characterized by progressive muscle degeneration
- Prevalence: Around 5 per 100,000 males
- Incidence: 1 in 3,500 male births
- Standard of Care: Corticosteroids

Drug candidates in development	Examples
Genetic and cell therapy	Exon Skipping (Eteplirsen, FDA-approved) Microdystrophin vectors (preclinical)
Myostatin Inhibitors	Domagrozumab (Pfizer, Phase 2)
Other symptomatic treatment	Idebenone (Santhera), approved in Israel
MAS Activators	Angiotensin 1-7 (preclinical) SARCONEOS (Biophytis)

SARCONEOS: PROOF OF CONCEPT IN ANIMAL MODEL OF DMD

SARCONEOS improves exercise tolerance in mdx mice



SARCONEOS reduces fibrosis and lesional profile in mdx mice muscles



SARCONEOS strongly improves muscle function and decreases muscle fibrosis in the standard animal model for Duchenne's muscular dystrophy (DMD)

SARCONEOS: CLINICAL DEVELOPMENT PLAN IN DUCHENNE'S MUSCULAR DYSTROPHY

MYODA-PK: Phase 1/2a PK study

- Phase 1/2 trial in 24 ambulant and non ambulant Duchenne boys
- Double-blind placebo-controlled study
- 2 phases: SAD, MAD (4 weeks)

MYODA-INT: Therapeutic efficacy Phase 2/3 study

- Multicentric international clinical trial, randomized, double-blind, placebo-controlled
- Minimal Duration: 6 months
- About 60 ambulant Duchenne boys
- Endpoints:
  - Primary: **North Star Ambulatory Assessment (NSAA) to measure functional motor abilities in children**
  - Secondary: **10 meters walk/run time, 1 min walk test, raise from the floor time**

PPAR ACTIVATORS AND RETINAL DISEASES

CHRONIC DISEASE:
DRY AGE-RELATED MACULAR DEGENERATION (AMD)

PAEDIATRIC ORPHAN DISEASE:
STARGARDT'S DISEASE

PHOTO-OXIDATIVE STRESS AND MACULAR DEGENERATION



A2E and oxydative stress

- A2E is a derivative of visual pigment
- A2E accumulates in Retinal Pigment Epithelium (RPE) cells
- A2E is a very reactive molecule that causes oxidative stress with exposure to light, leading to macular degeneration



Photo-oxidative stress leads to:

- Lipofuscin accumulation
- Drusen formation, distorts retina (affecting vision)
- Death of retina cells and progressive blindness



PPAR ACTIVATION

MACUNEOS activates PPAR nuclear receptors and protects the retina from oxidative stress associated with accumulation of A2E.



- ↓ Cell death
- ↓ Free radicals production
- ↓ VEGF production
- ↓ Inflammation

MACUNEOS is an activator of PPARs and limits the degeneration of the retina caused by photo-oxidative stress in the presence of A2E

DRY AGE-RELATED MACULAR DEGENERATION (AMD)

- Definition: All forms of AMD which are not neovascular and exsudative
- Prevalence: Estimated at 20M globally
- Standard of Care: Zinc + Vitamines C/E (nutraceuticals)

Drug candidates in development	Examples
Anti-complement factor antibodies	Lampaluzimab (Roche) – failed in Phase III
Visual Cycle Inhibitors	Emixustat (Acucela) – failed in Phase IIb/III
PPAR Activators	MACUNEOS (Biophytis)

MACUNEOS: PROOF OF CONCEPT IN ANIMALS

MACUNEOS preserves the retina's functionality and limits the A2E accumulation after chronic oral administration (ABCA4-/- RDH8-/- mice model)





MACUNEOS preserves the number of layers of photoreceptors after a light stress (Blue light rat model)



MACUNEOS protects the retina and preserves visual function in animal models of dry AMD or Stargardt's disease

MACUNEOS: SAFETY AND PROOF OF CONCEPT IN HUMANS

BIXILIA –Safety and PK in healthy volunteers

- 47 healthy volunteers
- Oral administration (35 mg/day) for 12 weeks
- Double-blind, placebo-controlled, nutrition study
- No serious adverse event
- Achieved target for bioavailability

MACA-PK – Phase 1/2a – Safety, PK and PD in patients with Dry AMD

- Phase 1/2a study, multicentric, international
- Three phases to explore various oral doses of Macuneos
  - SAD step in healthy volunteers (1 center in Belgium)
  - MAD step in 36 patients with dry AMD for 3 months (5 centers in France and Belgium)
- Endpoints
  - Safety and pharmacokinetics
  - Plasmatic biomarkers
  - Visual parameters: ERG, night vision and contrast vision, visual acuity

MACA-PK study evaluates the safety, the pharmacokinetics and the pharmacodynamics of MACUNEOS in patients with intermediate dry AMD

MACA: PHASE 2B INTERNATIONAL CLINICAL PROGRAM

MACA-OBS – Observational study in patients with dry AMD

- Multicentric observational study: clinical centers in Europe and the US
- 100 patients suffering of intermediate dry AMD
- Duration: 6 months
- Endpoints: atrophic lesion size, ERG, visual acuity

MACA-INT – Phase 2b multicentric clinical trial

- Multicenter randomized double-blind, placebo-controlled study
- 300 patients suffering of intermediate dry AMD
  - Macuneos 100mg vs Macuneos 350mg vs placebo
- Duration: 18 months (DSMB : intermediate milestone after 9 months)
- End points:
  - Primary: atrophic lesion size progression
  - Secondary: visual acuity, ERG, accumulation of lipofuscins, evolution towards wet AMD



STARGARDT'S DISEASE



- Definition: Genetically determined Juvenile Macular Degeneration
- Prevalence: Estimated at 1 in 10,000
- Standard of Care: Eyeglasses / Sunglasses
  Currently no approved therapeutic

Drug Candidates in Development
ABCA4 Gene Therapy (Sanofi)
Retinal stem cell grafts (Opsis Therapeutics)
Visual Cycle Inhibitor (Emixustat, Acucela)
PPAR Activator (MACUNEOS, Biophytis)

MACUNEOS preserves the retina structure after intra-vitreal injection (ABCA4-/- RDH8-/- mice model)



VALUE CREATION NEWS FLOW

SARCONEOS in SARCOPENIA

- H1 18: SARA-OBS: Interim results of the observational phase, in Europe and US
- H1 18: SARA-INT: Initiation of the interventional Phase 2b SARA
- H2 19: SARA-INT: Interim results of the interventional Phase 2b SARA (DSMB)
- H2 19**: SARA-INT: Results report of Phase 2b SARA**

SARCONEOS in DMD

- H1 18: Orphan drug designation
- H2 18: Initiation of MYODA-PK phase 1/2 clinical program in DMD
- 2019: Initiation of MYODA-INT phase 2/3 clinical program in DMD

MACUNEOS in Dry AMD

- H2 18: MACA-PK: Pharmacokinetics study in patients
- H2 18: MACA-OBS: Initiation of observational phase (ending H2 19)
- H1 19: **MACA-PK: Results report of Phase 1/2a MACA-PK**

THE BOARD OF DIRECTORS

Jean M. Franchi
Independant Board Member
- BA in Finance in Hofstra alumnus
- CFO for Merrimack Pharmaceuticals
- 30+ years as Finance Director for Biotech companies, including 15 years with Genzyme

Stanislas VEILLET
Chairman of the Board
- PhD in genetics, AgroParisTech alumnus
- 15+ years in biotech R&D management (Monsanto, Pharmacia, Danone)
- Created Biophytis in 2006

Eric ROWINSKY
Independent Board Member
- President of Rgenix and Oncology Scientific Director at Clearpath Development
- Editor in chief of the *Investigational New Drug* review
- 25 years experience in clinical research and in drug development

A BOARD OF DIRECTORS WITH COMPLEMENTARY PROFILES

Nadine COULM
Independant Board Member
- HEC alumnus
- IR Director for Korian
- 20 years of IR experience with FNAC BNP PARIBAS, DANONE & CASINO

Jean-Gérard GALVEZ
Independant Board Member
- INP Nancy & MBA Stanford alumnus
- Board member of Implanet & Echosens
- Co-Founder & ex CEO of ActivCard (Nasdaq)

Dimitri BATSIS
Independent Board Member
- Entrepreneur and Business Angel
- Founder of Zeni Corporation and Drone Volt
- 20 years experience in the new technologies' sector

CAPITAL STRUCTURE

Stock profile

- Market: Euronext Growth of Euronext Paris
- Ticker: ALBPS
- Shares outstanding: 13,463,413
- Share price (August 30th 2018): €2.61/share
- Market Capitalization: €35M



29

Thank you

Investors contact: investors@biophytis.com